

Supplementary table

Table S1. Meta-analyses and subgroup meta-analyses.

	ITT CRR	PP CRR	ITT ORR	PP ORR
Overall				
Studies, <i>N</i>	10	10	10	10
Patients, <i>N</i>	2246	1988	2246	1988
Events, <i>N</i>	945	945	1360	1360
Estimated proportion from random effect model, % (95% CI)	38 (31-46)	45 (37-53)	57 (48-66)	67 (57-77)
<i>I</i> ² , %	91.2	90.5	94.0	94.6
Location				

Estimated proportion from random effect model, % (95% CI)				
EU	31 (23-40)	37 (28-46)	48 (36-59)	56 (42-69)
USA	46 (37-56)	54 (45-63)	68 (63-74)	79 (75-82)
I ² , %				
EU	92.0	92.0	96.0	96.0
USA	85.0	80.0	60.0	0.0
<i>p</i> ^a	0.024	0.006	0.002	<0.001
Presence of PMBCL				
Estimated proportion from random effect model, % (95% CI)				
Presence	40 (28-53)	48 (37-60)	61 (48-73)	74 (63-83)
Absence	36 (27-46)	41 (30-53)	53 (40-66)	61 (45-76)

I^2 , %				
Presence	91.6	86.9	90.2	83.0
Absence	82.6	86.0	93.1	95.0
p^a	0.612	0.402	0.382	0.194

Bold values: statistically significant p value.

CRR, complete response rate; ITT, intention-to-treat; ORR, overall response rate; PMBCL, primary mediastinal large B-cell lymphoma; PP, per protocol.

^aCochran's Q test.

Table S2. Results of meta-regression.

		Complete response rate, intention to treat						Complete response rate, per protocol					
Model number	Variables included	Studies, <i>N</i>	R ² , %	residual I ² , %	b	SE(b)	<i>p</i>	Studies, <i>N</i>	R ² , %	residual I ² , %	b	SE(b)	<i>p</i>
1	Median follow-up	10	7.83	91.54	0.005	0.004	.168	10	7.86	90.71	0.005	0.004	.172
2	Percentage of infused patients	10	11.67	91.36	0.752	0.526	.153	10	0.00	92.06	0.393	0.591	.506
3	Percentage of bridging therapy ^a	8	24.27	90.52	-0.463	0.279	.097	8	41.71	86.23	-0.575	0.255	.024
		Overall response rate, intention to treat						Overall response rate, per protocol					
Model number	Variables included	Studies, <i>N</i>	R ² , %	residual I ² , %	b	SE(b)	<i>p</i>	Studies, <i>N</i>	R ² , %	residual I ² , %	b	SE(b)	<i>p</i>
1	Median follow-up	10	4.84	93.75	0.005	0.004	.237	10	0.00	94.77	0.005	0.005	.357
2	Percentage of infused patients	10	0.00	94.58	0.346	0.650	.594	10	0.00	95.34	-0.322	0.750	.675
3	Percentage of bridging therapy ^a	8	36.08	91.86	-0.635	0.299	.034	8	50.07	91.19	-0.850	0.312	.006

Bold values: statistically significant *p* value.

^aGhafouri et al. (2021) and Kittai et al. (2021) were excluded from the meta-regression of the proportion of patients receiving bridging therapy (BT) before infusion, since the proportion of BT in the updated databases was not available.

Fig. S1 Flow chart.




Fig. S2 Forest plot of the subgroup analysis according to type of product. A: CRR ITT; B: CRR PP; C: ORR ITT; D: ORR PP. CRR, complete response rate; ITT, intention-to-treat; ORR, overall response rate; PP, per protocol.




Fig. S3 Bubble plot of the meta-regression of the percentage of bridging therapy. A: CRR ITT; B: CRR PP; C: ORR ITT; D: ORR PP.

CRR, complete response rate; ITT, intention-to-treat; ORR, overall response rate; PP, per protocol.

